
Hydroquinone: Treats selected hyperpigmentation, including melasma, under an appropriate treatment plan. Kojic Acid: May help uneven pigmentation, often as part of a combination treatment.


Choose for diagnosed stubborn pigment with professional guidance and a defined review point.
Consider for uneven pigment if tolerated; evidence is mainly for combinations.
Can you use both?
Both lighten pigment and can irritate together. Follow your dermatologist's plan rather than stacking them.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.











Acts on tyrosinase pathways: Hydroquinone suppresses melanin synthesis. Targets excess pigmentation: Appropriate use and monitoring matter.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.

Reduces tyrosinase activity: Kojic acid interferes with melanin production. Less new pigment forms: Effects depend on the formula and tolerance.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.
Built from where each one usually sits in a routine. Introduce one at a time.
4% is a common clinician-directed hydroquinone strength. In the U.S., hydroquinone skin-lightening products are not legally marketed over the counter; higher compounded strengths are not routine starting points.
4%
Clinician-directed strength
Used in melasma treatment and in the approved combination TRI-LUMA. Treatment length and the complete formula require medical guidance.
Choosing a strength: Get a diagnosis and a treatment plan for the pigmented area rather than choosing solely by concentration.
Higher strengths: More is not automatically better. Irritation and blue-black discoloration called ochronosis are important risks, especially with inappropriate or prolonged use.
Formula matters: Single-ingredient creams, compounded blends and TRI-LUMA are different products. A combination containing a steroid or retinoid needs its own instructions.
Kojic acid concentrations in older studies differ from current cosmetic limits. In the EU, kojic acid is limited to 1% in face and hand products; that is not a universal treatment target.
1%
2%
EU cosmetic ceiling
The maximum in specified face and hand products. This is a regulatory limit, not proof of the best efficacy.
Older combination-study strength
Studied with hydroquinone and glycolic acid. The combination result does not isolate kojic acid or establish a current home-use recommendation.
Choosing a strength: Check local rules and the full formula. Kojic acid and kojic dipalmitate are different ingredients and cannot be compared by percentage alone.
Higher strengths: Do not use an older trial’s concentration as a reason to exceed current limits. Irritation or allergic contact dermatitis can occur.
Formula matters: Combination products may obtain benefit from several ingredients. A study of a combination cannot tell you what kojic acid alone contributed.
Approximate windows, not promises.
First few weeksAssess tolerance first; pigment change is usually slower.
First few weeksAssess tolerance first; pigment change is usually slower.
4–8 weeksSome studied regimens begin showing pigment improvement.
4–8 weeksSome studied regimens begin showing pigment improvement.
8–12 weeksA useful review point for benefit and irritation.
8–12 weeksA useful review point for benefit and irritation.
3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.
3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.
6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.
6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.
Can irritate; prolonged inappropriate use can cause paradoxical darkening (ochronosis).
Can cause stinging, redness or contact dermatitis.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Do not use to lighten normal skin broadly or continue through worsening pigmentation. US nonprescription hydroquinone skin-lightening products are not legally marketed.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
More of it is absorbed through the skin than with most topicals, so it is usually stopped. Azelaic acid is the common substitute. Ask the doctor managing your pregnancy.
There is not much pregnancy-specific data on kojic acid, and melasma often appears or worsens in pregnancy. Ask the doctor managing your pregnancy first. Azelaic acid and strict sun protection are the usual alternatives.
On the skin. The finished product delivers hydroquinone in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. Suppresses melanin synthesis through tyrosinase-related activity; targeted use and monitoring matter.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
On the skin. The finished product delivers kojic acid in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. Inhibits tyrosinase activity involved in melanin production; cosmetic formulas differ from studied combinations.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
Choose for diagnosed stubborn pigment with professional guidance and a defined review point.
The reviewed active-comparator melasma study was small with substantial attrition. Hydroquinone has broader clinical use, but this comparison does not support indefinite treatment or unsupervised high strengths.
Consider for uneven pigment if tolerated; evidence is mainly for combinations.
A 40-woman split-face trial added kojic acid to hydroquinone and glycolic acid. It does not show that kojic acid alone performs as well as the combination or that higher strengths are better.
Sources